Cardioversion of chronic atrial fibrillation-towards a more aggressive approach.

Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J (2000) 1.45

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol (2001) 3.65

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J (2001) 3.34

ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation (2001) 3.13

Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (1998) 1.47

Influence of residual myocardial ischaemia on induced ventricular arrhythmias following a first acute myocardial infarction. Eur Heart J (2001) 1.43

[Value of systematic preventive antibiotherapy in cardiac pacemaker implantation]. Ann Cardiol Angeiol (Paris) (1991) 1.08

Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol (2006) 1.07

International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace (2003) 1.06

Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators. J Am Coll Cardiol (2000) 1.06

Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology (1997) 1.04

Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol (1997) 0.97

[Heart perforation following transvenous implantation of a cardiac pacemaker]. Presse Med (1999) 0.96

Incidence of perforation and other mechanical complications during dual active fixation. Pacing Clin Electrophysiol (1996) 0.95

Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost (1999) 0.90

[Wolff-Parkinson-White syndrome. Correlation between the results of electrophysiological investigation and exercise tolerance testing on the electrical aspect of preexcitation]. Arch Mal Coeur Vaiss (1979) 0.89

External cardioversion of atrial fibrillation: comparison of biphasic vs monophasic waveform shocks. Europace (2001) 0.88

Alteration of Na,K-ATPase isoenzymes in diabetic cardiomyopathy: effect of dietary supplementation with fish oil (n-3 fatty acids) in rats. Diabetologia (1997) 0.88

Genetics of the PTS components in Escherichia coli K-12. FEMS Microbiol Rev (1989) 0.86

Internal low-energy cardioversion: a therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion. Europace (1999) 0.84

[Percutaneous electric interruption of normal auriculoventricular conduction. Analysis of French cases]. Arch Mal Coeur Vaiss (1986) 0.82

Treatment of hepatitis C patients with normal aminotransferases levels. Clin Liver Dis (1999) 0.81

[In vitro malignant transformation of fetal hamster brain cells by benzo (a) pyrene]. C R Acad Sci Hebd Seances Acad Sci D (1976) 0.81

Catheter ablation using very high frequency current: effects on the atrioventricular junction and ventricular myocardium in sheep. Europace (2002) 0.81

Pacing-induced alternate Wenckebach periods: incidence and clinical significance. Pacing Clin Electrophysiol (1979) 0.80

Nodular regenerative hyperplasia of the liver associated with a Factor V Leiden mutation. Eur J Gastroenterol Hepatol (1998) 0.80

Dietary fish oil promotes positive inotropy of ouabain in the rat heart. Am J Physiol (1999) 0.79

Cholesterol and omega-3 fatty acids inhibit Na, K-ATPase activity in human endothelial cells. Atherosclerosis (1999) 0.79

Electrophysiology of tiapamil in humans. Cardiology (1982) 0.78

[Supraventricular tachycardia induced by effort and by catecholamines]. Arch Mal Coeur Vaiss (1985) 0.78

Specific up-regulation of mitochondrial F0F1-ATPase activity after short episodes of atrial fibrillation in sheep. J Cardiovasc Electrophysiol (2000) 0.78

[Complex ventricular extrasystole. Value of technics of programmed electric stimulation]. Arch Mal Coeur Vaiss (1987) 0.78

Remote occurrence of high degree heart block following failure of transcatheter AV junctional ablation: incidence and clinical significance. Pacing Clin Electrophysiol (1987) 0.77

A new method for evaluating the effect of antiarrhythmic drugs on atrioventricular nodal conduction. Br Heart J (1986) 0.75

Is the implantable cardioverter-defibrillator cost-effective? Eur Heart J (1996) 0.75

Effects of digoxin on chemoreflex in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand) (2001) 0.75

Intravenous digoxin: still the drug of choice for acute termination of atrial fibrillation? Eur Heart J (1997) 0.75

[Parkinson syndrome, a possible adverse effect of calcium inhibitors]. Arch Mal Coeur Vaiss (1992) 0.75

Trans-septal catheterization: a new frontier in clinical electrophysiology? Eur Heart J (1998) 0.75

Atrioventricular junctional ablation and pacing for paroxysmal atrial fibrillation: the Barcelona recommendations. Europace (1999) 0.75

Parkinson's disease: a new risk factor for gallstone disease? J Hepatol (1995) 0.75

[Sequential double demand programmable stimulation in the treatment of resistant supraventricular tachycardia. Long-term results]. Arch Mal Coeur Vaiss (1983) 0.75

[Apropos of a government memorandum of 29 December 1994 and a 16 March 1995 ordinance relative to the use of disposable sterile medical equipment]. Arch Mal Coeur Vaiss (1995) 0.75

[Wolff-Parkinson-White syndrome. Outcome of patients treated with anti-arrhythmia agents from data of electrophysiological examinations]. Arch Mal Coeur Vaiss (1988) 0.75

[Carcinoid cardiopathy: value of ultrasonography and MRI. Apropos of a case related to bronchial tumor. Review of the literature]. Ann Cardiol Angeiol (Paris) (1989) 0.75

Intrapulmonary artery coiling of a permanent pacing lead. Clin Cardiol (1994) 0.75

Electrocardiographic characteristics of the escape rhythm in transient complete atrioventricular block induced by transcatheter electrical ablation of the atrioventricular junction. Pacing Clin Electrophysiol (1988) 0.75

Plasma beta-endorphin and adenosine concentration in pulmonary hypertension. Am J Cardiol (2000) 0.75

[Unstable angina and single vessel stenosis of the anterior interventricular artery. Evaluation of the threatened myocardium. Therapeutic implications]. Ann Cardiol Angeiol (Paris) (1983) 0.75

[Cardiac Doppler in the selection of patients for aortic valvuloplasty. Comparison with data of phonomecanograms]. Ann Cardiol Angeiol (Paris) (1988) 0.75

[Ventricular arrhythmia following repair of Fallot's tetralogy. Apropos of 59 cases]. Arch Mal Coeur Vaiss (1985) 0.75

Membrane markers, karyotypic abnormalities, ultrastructure and functional properties of lymphocytes in a case of 'D-cell' chronic lymphatic leukemia. Leuk Res (1984) 0.75

[Coronary angioplasty immediately after coronary recanalization in the acute phase of myocardial infarct]. Ann Cardiol Angeiol (Paris) (1983) 0.75

[Long-term treatment of arrhythmias with fenoxedil chlorhydrate]. Arch Mal Coeur Vaiss (1983) 0.75

[Occlusive spasm of a coronary artery not treated during angioplasty. Apropos of a case]. Ann Cardiol Angeiol (Paris) (1993) 0.75

[Recommendations on the practice of intracavitary diagnostic methods and treatment of cardiac arrhythmias. Diagnostic electrophysiology; interventional electrophysiology; permanent cardiac stimulation; automatic implantable defibrillators]. Arch Mal Coeur Vaiss (1998) 0.75

[Treatment of recurrent ventricular tachycardia with hydroquinidine. Evaluation of its efficacy with electrophysiological technics]. Arch Mal Coeur Vaiss (1985) 0.75

[Electro-mechanical dissociation concomitant with myocardial reperfusion in the acute phase of myocardial infarction]. Arch Mal Coeur Vaiss (1987) 0.75

[Prevalence of alcoholic diseases. At a teaching hospital of the Paris suburbs]. Presse Med (1990) 0.75

[Hereditary resistance to vitamin K antagonists. Apropos of a case]. Arch Mal Coeur Vaiss (1999) 0.75

[Coronary occlusion immediately following a successful coronary angioplasty. Treatment by repeat angioplasty]. Ann Cardiol Angeiol (Paris) (1985) 0.75

[Reduction of ventricular tachycardia by programmed electric stimulation. Clinical implications]. Arch Mal Coeur Vaiss (1987) 0.75

[Oral and intravenous bepridil in the treatment of recurrent sustained ventricular tachycardias. Electropharmacological study]. Arch Mal Coeur Vaiss (1985) 0.75

[Total or partial electrical interruption of the atrioventricular pathway. Evaluation of clinical results and indications]. Arch Mal Coeur Vaiss (1986) 0.75

[Radiofrequency ablation of resistant atrial flutter: a new anatomical approach]. Arch Mal Coeur Vaiss (1997) 0.75

[Coronarography by percutaneous puncture of the axillary artery. Value in arteriopathies of the lower limbs]. Arch Mal Coeur Vaiss (1984) 0.75

[Interview with S. Lévy. Apropos of recommendations on defibrillators. Interview by M. Hérida]. Presse Med (1998) 0.75

[Implantable defibrillators. Good cost-effectiveness or supplementary expense to our hospitals?]. Arch Mal Coeur Vaiss (1999) 0.75

[Electrophysiologic evaluation and follow-up of patients with a syncopal episode of unknown origin]. Arch Mal Coeur Vaiss (1990) 0.75

[How to evaluate a conduction disorder?]. Presse Med (1984) 0.75

Alternate ventriculo-atrial Wenckebach conduction during ventricular tachycardia. Pacing Clin Electrophysiol (1985) 0.75

[Internal electric shock: a new possibility for the reduction of permanent auricular fibrillation]. Presse Med (1987) 0.75

[Treatment of recurrent ventricular tachycardias using oral propafenone]. Arch Mal Coeur Vaiss (1985) 0.75

[Sinus dysfunction associated with catecholaminergic ventricular tachycardia. Therapeutic implications]. Arch Mal Coeur Vaiss (1986) 0.75

Left ventricular pressure measurement during noninvasive transcutaneous cardiac pacing. Pacing Clin Electrophysiol (1989) 0.75

Inhibition of Na,K-ATPase by external electrical cardioversion in a sheep model of atrial fibrillation. J Cardiovasc Electrophysiol (2000) 0.75

[Acute effects of nicardipine on the vascular reactivity of oxygen in patients with respiratory insufficiency and pulmonary hypertension]. Arch Mal Coeur Vaiss (1993) 0.75

[Exercise test in isolated anomalies of auriculo-ventricular conduction in children and adolescents. Value in idiopathic auriculo-ventricular blocks and ventricular pre-excitation syndromes]. Arch Mal Coeur Vaiss (1984) 0.75

[Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. Ann Cardiol Angeiol (Paris) (1993) 0.75

Transvenous cardioversion of atrial fibrillation using low-energy shocks. J Interv Card Electrophysiol (1997) 0.75

[Ventricular tachycardia: definitions, mechanisms and treatment]. Rev Prat (1986) 0.75

[Percutaneous aortic valvuloplasty by trans-septal approach]. Arch Mal Coeur Vaiss (1987) 0.75

Canine cardiac digitalis receptors are preserved in congestive heart failure induced by rapid ventricular pacing. J Recept Signal Transduct Res (1997) 0.75

Cirrhosis: a new, but expected cause of biliary sludge. Alcohol Clin Exp Res (1997) 0.75

Sudden death as a presenting symptom of hypertrophic cardiomyopathy: treatment with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol (1996) 0.75

[Implantable ventricular defibrillator. Systematic induction of ventricular arrhythmia is not useful except for implantation]. Arch Mal Coeur Vaiss (1999) 0.75

[Cardioversion of atrial fibrillation with low energy internal electric shock]. Arch Mal Coeur Vaiss (1997) 0.75

[Pharmacological treatment of ventricular tachycardia]. Arch Mal Coeur Vaiss (1993) 0.75

[Monitoring of hemostasis during liver transplantation: contribution of thromboelastography]. Ann Fr Anesth Reanim (1993) 0.75

[Comparative effects of anti-arrhythmia agents on ventricular refractory period and prevention of ventricular tachycardia induced by stimulation]. Arch Mal Coeur Vaiss (1992) 0.75

[Relations between the site of significant monotruncular coronary stenosis and left ventricular function. Therapeutic implications]. Arch Mal Coeur Vaiss (1983) 0.75

[Recommendations for good practice of intracavitary techniques for diagnosis and treatment of cardiac arrhythmia. Diagnostic electrophysiology; interventional electrophysiology; permanent cardiac stimulation; implantable automatic defibrillators]. Arch Mal Coeur Vaiss (1994) 0.75

[Long-term follow up of surgically-treated congenital heart disease: interauricular communication, aortic coarctation, tetralogy of Fallot]. Ann Cardiol Angeiol (Paris) (1983) 0.75

[Atrioventricular block at nodal and infrahissian level during atrial tachycardia. Apropos of a case]. Arch Mal Coeur Vaiss (1992) 0.75

Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias. Cardiovasc Drugs Ther (1995) 0.75

Torsades de pointes. A clearly defined syndrome or an electrocardiographic curiosity? Int J Cardiol (1985) 0.75

[Intravenous sotalol in the acute treatment of supraventricular tachycardias]. Arch Mal Coeur Vaiss (1986) 0.75

[Percutaneous venoplasty for the implantation of a dual-chamber cardiac pacemaker]. Arch Mal Coeur Vaiss (1994) 0.75

[Automobile drivers' licensing and heart rhythm disorders. On what criteria should recommendations be bases?]. Arch Mal Coeur Vaiss (1998) 0.75

[Changes in homeostasis during surgical liver resection]. Ann Fr Anesth Reanim (1999) 0.75

[Hemopericardium after coronary recanalization with streptokinase in the acute phase of myocardial infarction. Drainage and early aortocoronary bypass on the 4th day]. Arch Mal Coeur Vaiss (1983) 0.75